Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Booz Allen Hamilton Holding Corporation (BAH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Booz Allen Hamilton Holding Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Booz Allen Hamilton Holding Corporation trades at $63.35 (market cap $7.53B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 5.3× Booz Allen Hamilton Holding Corporation's market cap, and Booz Allen Hamilton Holding Corporation pays a 3.76% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BAH | |
|---|---|---|
Market Cap | $39.89B | $7.53B |
Sector | Health | Industrials |
52-Week High | $491.22 | $115.95 |
52-Week Low | $278.09 | $59.71 |
Enterprise Value | $38.15B | $10.92B |
Dividend Yield | — | 3.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Booz Allen Hamilton (BAH) trades at $62.76, down 0.63% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 9.1 and robust profitability, including an 80.17% ROE. Recent earnings have mostly beaten estimates, and the company announced a partnership with OpenAI to advance AI in national security. Cash flow from operations improved to $1.01B in 2025, though net cash flow turned negative in 2026 projections.
BAH presents a compelling value opportunity with solid earnings growth and a consensus price target of $80.80, implying significant upside. Risks include persistent civil segment weakness noted in guidance and rising debt-to-asset ratios. Investor sentiment is mixed, with nearly half of analysts rating it a buy, but technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →
